BlueCrest Capital Management’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

BlueCrest Capital Management’s Portfolio DMIIU Stock Details DMIIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.54M	Hold	250,000	–	–	0.08%	150
2026 Q1	$2.51M	Hold	250,000	–	–	0.15%	123
2025 Q4	$2.5M	Hold	250,000	–	–	0.08%	83
2025 Q3	$2.49M	Buy	+250,000	New	+$2.49M	0.06%	105

Other funds holding DMIIU

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

LGM

L1 Global Manager Melbourne $142M AUM

RAM

Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlueCrest Capital Management's DMIIU Position: Q2 2026 in Review

BlueCrest Capital Management held its Drugs Made In America Acquisition II Corp Unit (DMIIU) position steady in Q2 2026 at 250,000 shares worth $2.54M. The position accounts for 0.08% of the portfolio, ranked #150.

BlueCrest Capital Management first reported a position in DMIIU in Q3 2025 and has held it in 4 quarters since. 11 funds tracked by Wall St. Rank hold DMIIU as of Q2 2026.

BlueCrest Capital Management held 250,000 shares of Drugs Made In America Acquisition II Corp Unit worth $2.54M as of Q2 2026.
BlueCrest Capital Management left its Drugs Made In America Acquisition II Corp Unit share count unchanged in Q2 2026.
Drugs Made In America Acquisition II Corp Unit made up 0.08% of BlueCrest Capital Management's portfolio in Q2 2026, its #150 holding.
BlueCrest Capital Management first reported a position in Drugs Made In America Acquisition II Corp Unit in Q3 2025 and has held it in 4 quarters since.
11 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q2 2026.

Based on BlueCrest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.